Latest Pyrazines Stories
SOUTH SAN FRANCISCO, Calif., May 18, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc.
QUEBEC CITY, April 4 /PRNewswire/ - Aeterna Zentaris Inc.
CALGARY, Nov. 1 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that an abstract covering preclinical research with reovirus (REOLYSIN((R))) is available on the European CanCer Organisation (ECCO) website at www.ecco-org.eu.
A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADEÂ®), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma.
EMERYVILLE, Calif., June 8 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
MENLO PARK, Calif., May 18 /PRNewswire/ -- A recently completed randomized trial compared three ways to deliver a behavioral smoking cessation program using varenicline (ChantixÂ®): by phone, web, or both.
SUNNYVALE, Calif., April 15 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced multiple presentations covering its Btk and HDAC programs at the American Association for Cancer Research (AACR) 2010 Annual Meeting being held April 17-21 in Washington, DC.
Company Has Also Requested Scientific Advice on its Phase 3 Program with Perifosine in Refractory Advanced Colorectal Cancer. QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
WALTHAM, Mass., Jan.
Carfilzomib induces a response in 45 percent of patients and reduces neuropathy.